Entera Bio

Entera is a clinical stage biotech company focused on transforming care through oral peptide therapies.

[Entera Bio @enterabio]

$ENTX Correction: Entera to Participate in Upcoming Fall Investor Conferences

Read the Full News Release 👉 https://t.co/JkZEMv2Bcu

[Entera Bio @enterabio]

$ENTX Entera to Participate in Upcoming Fall Investor Conferences

Read the Full News Release 👉 https://t.co/B6OVAvYMXl

[Entera Bio @enterabio]

$ENTX Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Read the Full News Release 👉 https://t.co/2obUTWQ5dT

[Entera Bio @enterabio]

$ENTX Entera Announces Second Quarter 2026 Financial Results and Business Updates

Read the Full News Release 👉 https://t.co/23gCUyTLSf

[Entera Bio @enterabio]

$ENTX Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Read the Full News Release 👉 https://t.co/zlfktWnZXZ

[Entera Bio @enterabio]

$ENTX Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

Read the Full News Release 👉 https://t.co/OCEtnZ4cOP

[Entera Bio @enterabio]

$ENTX Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Read the Full News Release 👉 https://t.co/tQ1qZlKBSt

[Entera Bio @enterabio]

$ENTX Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Read the Full News Release 👉 https://t.co/weTRuLmwRt

[Entera Bio @enterabio]

$ENTX ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Read the Full News Release 👉 https://t.co/2WpW0NaiVm

[Entera Bio @enterabio]

We’re joining the ASBMR White Sneakers Challenge this May. White sneakers = a commitment to build and protect strong bones at every age.

Join us and share how you move!

#WhiteSneakersCampaign​​​​​​​​​​​​​​​​ #ASBMR #BoneHealth $ENTX

[Entera Bio @enterabio]

$ENTX Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Read the Full News Release 👉 https://t.co/Ju8hDHPklq

[Entera Bio @enterabio]

$ENTX Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Read the Full News Release 👉 https://t.co/L1m43E9E9n

[Entera Bio @enterabio]

$ENTX Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Read the Full News Release 👉 https://t.co/tt9TLkQ85o

[Entera Bio @enterabio]

$ENTX Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

Read the Full News Release 👉 https://t.co/tqghhKTCvU

[Entera Bio @enterabio]

$ENTX Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Read the Full News Release 👉 https://t.co/mbCuL9RK89

[Entera Bio @enterabio]

$ENTX Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference

Read the Full News Release 👉 https://t.co/fusQnxwIz2

[Entera Bio @enterabio]

$ENTX Entera Bio Announces Open Market Purchases of Company Stock by Board Members

Read the Full News Release 👉 https://t.co/FEU0EsI3UT

[Entera Bio @enterabio]

$ENTX Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Read the Full News Release 👉 https://t.co/fLNMMKnbcx

[Entera Bio @enterabio]

$ENTX OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Read the Full News Release 👉 https://t.co/VtPfiByCvE

[Entera Bio @enterabio]

$ENTX Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

Read the Full News Release 👉 https://t.co/dyi0npqU0y